Equity Overview
Price & Market Data
Price: $0.88
Daily Change: -$0.0722 / 8.20%
Daily Range: $0.879 - $1.03
Market Cap: $171,476,400
Daily Volume: 1,180,579
Performance Metrics
1 Week: -10.04%
1 Month: -28.23%
3 Months: -14.42%
6 Months: -39.86%
1 Year: 94.24%
YTD: -13.59%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.